Target General Information
Target ID T52450
Target Name Matrix metalloproteinase-1
Synonyms Fibroblast collagenase; MMP-1; Matrix metalloproteinase-1; MMP1
Target Type Successful
Gene Name MMP1
Biochemical Class Peptidase
UniProt ID MMP1_HUMAN
Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals
Disease Lung cancer
Example drug Prinomastat Approved [536056], [541642], [1572592]
Tissue Lung tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 4.53
Z-score: 2.57
P-value: 2.68E-70
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: 4.82
Z-score: 2.67
P-value: 2.00E-48
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Prostate cancer
Example drug Prinomastat Approved [536056], [541642], [1572592]
Tissue Prostate
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.32
Z-score: 0.19
P-value: 7.68E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Rheumatoid arthritis
Example drug CIPEMASTAT Phase 3 [532656], [541601], [1572592]
Tissue Synovial tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 5.07
Z-score: 1.67
P-value: 2.10E-02
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Sarcoma
Example drug BMS 275291 Discontinued in Phase 3 [536608], [1572592]
Tissue Muscle tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.99
Z-score: 3.23
P-value: 7.25E-65
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: 1.03
Z-score: 8.06
P-value: 5.24E-17
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Multiple sclerosis
Tissue Spinal cord
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: -0.03
Z-score: -0.36
P-value: 9.20E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target Gene Expression Profiles in Other Tissues of Healthy Individuals
Reference
Ref
Ref 541601(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6466).
Ref 541642(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6505).
Ref 536056Emerging therapies for neuropathic pain. Expert Opin Emerg Drugs. 2005 Feb;10(1):95-108.
Ref 536608Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8.
Ref 532656Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8.
Ref 1572592NCBI GEO: archive for functional genomics data sets--update.

If you find any error in data or bug in web service, please kindly report it to Dr. Wang and Dr. Li.